Risk mitigation in Crohn's disease and ulcerative colitis: Session four summary.

Leong, Rupert W

Leong, Rupert W.

Leong RW; Department of Gastroenterology and Hepatology, Concord General Repatriation Hospital, Sydney, Australia and the University of Sydney, Sydney, Australia.

J Gastroenterol Hepatol ; 36 Suppl 1: 27-28, 2021 Apr.

Article in English | MEDLINE | ID: covidwho-1186170

Subject(s)

Colitis, Ulcerative/drug therapy; Crohn Disease/drug therapy; Risk Assessment; Risk Management/methods; Adrenal Cortex Hormones/administration & dosage; Adrenal Cortex Hormones/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Biological Products/adverse effects; Biological Products/therapeutic use; Clinical Decision-Making; Humans; Immunosuppressive Agents/adverse effects; Immunosuppressive Agents/therapeutic use; Molecular Targeted Therapy; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Risk Management / Colitis, Ulcerative / Crohn Disease / Risk Assessment Type of study: Prognostic study Limits: Humans Language: English Journal: J Gastroenterol Hepatol Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: Jgh.15456

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google